Cellect Biotechnology Completes Scale-Up Of Clinical Grade FasL; Enabling Stem Cell Therapy

Creative Commons License Tel Aviv. Source:  Volker Glätsch , no changes made.
Advertisement

Cellect Biotechnology Ltd. has announced that it has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced supplier.

Founded in 2011, located in Tel Aviv, Isreal, Cellect Biotechnology has developed a breakthrough technology for the selection of stem cells from any given tissue to any application of those cells. The technology aims to improve a variety of cell-based therapies.

The Company’s technology is expected to provide research institutes, hospitals and pharma companies with the tools to rapidly produce stem cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s ongoing cancer clinical trial is treating patients undergoing bone marrow transplantations.

Based on its process and the results of the ongoing clinical trial, the company has scaled up manufacturing of FasL for hundreds of personal batches and is fully scalable to hundreds of thousands of batches for clinical and collaborative purposes. The Company expects to form an alliance of clinical and commercial cell therapy centers using the ApoGraft™ technology.

The FasL protein is central to Cellect’s technology of cell separation and functional selection of stem cells and is the key active ingredient in Cellect’s ApoGraft™ and Apotainer product lines. Cellect’s FasL based technology is intended to enable achieving stem cells for any indication in quality, quantity and at a competitive price; and is expected to improve the safety and efficacy of stem cell therapies and regenerative medicine.

“The proven scalability of our clinical grade production of FasL is a major step forward and opens the door for multiple global clinical activities and collaborations, as well as supporting our existing and planned global partners. This is an important milestone to becoming the standard enabling technology for the enrichment of stem cells and manufacturing of any adult stem cell-based products for companies developing stem cell therapies and for researchers and academia engaged in adult stem cell research. We are committed to enabling a multi-billion global market over the next five years while positioning Cellect towards potentially meeting commercial demand for millions of patients worldwide in need of stem cell therapy, as well as providing raw materials for stem cell research centers and the biobanking industry.” – Dr. Shai Yarkoni, Cellect CEO

Sources:

  1. https://www.prnewswire.com/news-releases/completion-of-manufacturing-of-clinical-grade-fasl-enables-cellect-to-expedite-u-s-clinical-programs-into-multiple-studies-828865762.html
  2. https://www.linkedin.com/company/cellect-biotechnology/about/
Advertisement

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.